Sundia MediTech Appoints Three New Independent Board Members
Published: Sep 27, 2012
SHANGHAI, Sept. 27, 2012 /PRNewswire/ -- Sundia MediTech Group, a leading China-based CRO service company announced today that Albert Liou, Haibo Wang, and Wilma Wei have been appointed as Independent Board Members to its Board of Directors, effective immediately. These appointments will expand the Company's board from four to seven members. The Sundia Board of Directors is responsible for the direction, strategy, organization and administration of the Company.
"We are very pleased to welcome our independent board members. They bring a strong track record in pharmaceutical industry, financial community and corporate management, as well as a global outlook together with in-depth knowledge of business operation," said Ms. Cathy Yen, Sundia Chairman, who took the helm of the board in February. "I am sure their experience and insight will greatly assist us in the future development of the group to better serve our customers as well as in the establishment of policies and practices to support stronger corporate governance," She added.
Mr. Albert Liou serves as the Chairman of Fidelitas International Corporation, engaging in the investment of biotech medical equipment industry. Meanwhile he serves as the Chairman of ARDIC Instruments Co., focusing on pipeline of analytical instruments for educational, research, and industrial applications in nanotechnology. He also serves as Vice President of PAREXEL International, a leading global bio/pharmaceutical service organization, with main duties focusing on client relationships, business development and strategic initiatives in 13 countries in the Asia Pacific region including Taiwan, China, Japan, Korea, Singapore, and India etc. Mr. Liou has over 25 years of clinical research experience, of which 11 years were spent in the United States and 14 years in Asia.
Mr. Haibo Wang, President and CEO of Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (FDZJ), where he oversees all the company's businesses and divisions. He is also the Chairman of FDZJ's Board of Directors. Prior to FDZJ, Mr. Wang served as the supervisor of Pudong Productivity Promotion Center and Associate Professor of Fudan University; meanwhile, he worked for Zhejiang Shenghua Biok Biology Co. Ltd., a listed company in the PRC, serving as the chief technology officer. He presided over the New Drug for R&D and development, including Avermectin, Maduramicin and Ivermectin. Now, he serves as the expert of National Significant Creation of new drugs.
Ms. Wilma Wei received her MBA from University of Washington in Seattle in 1980's. Her career started from financial industry with experiences in cross border M&A, fund raising and structured finance. She was CFO of an electronic company for 10 years and she is now in charge of strategic investment in one of the reputable electronic companies in Taiwan.
SOURCE Sundia Meditech Company, Ltd.